Base to Base biotech podcast 5: Vitalant’s vital role in blood products, and Brainomix gives hope to stroke victims

This week on the podcast, we have a conversation with Vitalant’s Kevin Land, executive medical director, Biotherapies, and VP of Clinical Services, and Becky Cap, SVP, Biotherapies; and chat with Brainomix CEO and co-founder Michalis Papadakis about making a difference in getting faster treatments for stroke victims.Times: 01:52 Brainomix 21:44 VitalantVitalantVitalant, which used to be known as Blood Systems Inc., is a US nonprofit organization that collects blood from volunteer donors and provides blood, blood products and services across the US.It is the country’s largest independent, nonprofit blood services provider exclusively focused on providing blood and comprehensive transfusion medicine services. The organization has a network of about 120 donation centres and provides blood to about 900 hospitals in the US.Its operations, including blood services, biotherapies, laboratory and clinical services, information technology, supply chain, and marketing and sales.The Vitalant Research Institute is located in San Francisco with a second campus in Denver.We spoke with Vitalant’s Kevin Land, executive medical director, Biotherapies, and VP of Clinical Services, and Becky Cap, SVP, Biotherapies.BrainomixBrainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis.With origins as a spinout from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the US, and operations in more than 20 countries.A private company, backed by leading healthtech investors, Brainomix has created award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with a stroke imaging solution, driving increased treatment rates and improving functional independence for patients.The company recently raised £14m in a series C funding round.We spoke with the company’s CEO and co-founder, Michalis Papadakis.To get in touch, including with guest suggestions, please email [email protected]